Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
The Thyroid Gland01:23

The Thyroid Gland

The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustainable vitreoretinal surgery: balancing environmental responsibility with patient choice.

Eye (London, England)·2026
Same author

Surgical Management and Outcomes of Large High Myopic Macular Holes: Global Macular Hole Multicenter Study 3.

Retina (Philadelphia, Pa.)·2026
Same author

Modernising patient education in vitreoretinal surgery.

Eye (London, England)·2026
Same author

The Visual Effectiveness and Cost-Effectiveness of Vitrectomy and Membrane Peeling for Primary Idiopathic Epiretinal Membranes (iERMs): A Systematic Review.

Journal of ophthalmology·2026
Same author

OphthoEvidence report: Baseline structural optical coherence tomography biomarkers predictive of visual acuity following epiretinal membrane surgery-A systematic review and meta-analysis protocol.

PloS one·2025
Same author

Development of a core outcome set for patients with epiretinal membranes: a Delphi consensus study.

The British journal of ophthalmology·2025

Related Experiment Video

Updated: May 27, 2026

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

Low dose orbital radiotherapy for thyroid eye disease.

James F T Li Yim1, Teresa Sandinha, Jan M Kerr

  • 1Tennent Institute of Ophthalmology, Glasgow, Scotland. jamesly@doctors.org.uk

Orbit (Amsterdam, Netherlands)
|December 3, 2011
PubMed
Summary

Low-dose orbital radiotherapy effectively reduced the clinical activity score in patients with thyroid eye disease (TED). This treatment demonstrated significant improvement regardless of disease severity, offering a valuable therapeutic option.

More Related Videos

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

Related Experiment Videos

Last Updated: May 27, 2026

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Radiation Oncology

Background:

  • Thyroid eye disease (TED) management remains challenging, with low-dose orbital radiotherapy (LOR) use being debated.
  • Active TED often requires immunosuppression, which may have significant side effects.

Purpose of the Study:

  • To evaluate the efficacy of low-dose orbital radiotherapy (20 Gray) in treating active thyroid eye disease (TED).
  • To assess the impact of LOR on clinical activity scores and immunosuppression requirements in TED patients.

Main Methods:

  • Retrospective review of 59 consecutive TED patients treated with 20 Gy LOR over 12 fractions.
  • Data collected included symptom duration, pre- and post-treatment clinical activity scores (CAS), and immunosuppression needs.

Main Results:

  • LOR significantly reduced mean CAS from 3.17 to 0.73 (P < 0.001) at a mean follow-up of 6.5 months.
  • Only 5 patients remained on steroids post-treatment, and only 1 had CAS ≥ 3 at last follow-up.
  • CAS reduction was observed across all disease severity subgroups, including mild, moderate, severe TED, and optic neuropathy.

Conclusions:

  • Low-dose orbital radiotherapy is a valuable treatment for active thyroid eye disease.
  • LOR effectively reduces disease activity irrespective of initial severity, decreasing the need for ongoing immunosuppression.